Key result
Telmisartan reduced diastolic blood pressure significantly more than perindopril (WMD -2.05 mmHg) in patients with essential hypertension, with no significant difference in systolic blood pressure reduction.
Why the study?
The comparison of antihypertensive effects between telmisartan and perindopril was controversial in patients with essential hypertension.
Does telmisartan improve blood pressure reduction compared to perindopril in patients with essential hypertension?
Meta-Analysis (n=753)
Does telmisartan improve blood pressure reduction compared to perindopril in patients with essential hypertension?
Telmisartan provides a greater reduction in diastolic blood pressure compared to perindopril in patients with essential hypertension, though systolic blood pressure reduction is similar.
Answers are grounded in this paper and cite their sources.
Supports telmisartan preference for diastolic BP control over perindopril; extends comparative ARB-ACEI efficacy data in essential hypertension.
OBJECTIVE: We performed this meta-analysis determining the antihypertensive effect of telmisartan versus perindopril in patients with essential hypertension. BACKGROUND: The comparison of antihypertensive effects between telmisartan and perindopril were controversial. METHODS: Pubmed, Web of Science, and Cochrane Central were searched for all published studies. RESULTS: The antihypertensive effects were assessed in 753 patients included in 7 trials with a mean follow-up of 20 ± 16 weeks. There was no significant difference between telmisartan and perindopril in reduction of systolic blood pressure (SBP, weighted mean differences (WMD) 0.02 (95% confidence interval (CI), ‒2.78, 2.81) mm Hg, p > 0.05). The reduction of diastolic BP (DBP) treated with telmisartan was greater than perindopril in these patients (WMD ‒2.05 (95% CI, ‒2.60, ‒1.49) mm Hg, p < 0.001). Considering the effects of different doses on BP reduction, a sub-analysis was performed. The reduction of DBP treated with 40 mg/day telmisartan was greater than 4‒5 mg/day perindopril (WMD ‒2.18 (95% CI, ‒2.83, ‒1.53) mm Hg, p 0.05). CONCLUSION: The reduction of DBP is greater treated with telmisartan than perindopril in patients with essential hypertension (Tab. 2, Fig. 4, Ref. 34). Text in PDF www.elis.sk Keywords: essential hypertension, blood pressure, telmisartan, perindopril, meta-analysis.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2023) conducted a meta-analysis in Essential hypertension (n=753). Telmisartan vs. Perindopril (2-10 mg/day) was evaluated on Reduction of diastolic blood pressure (DBP) (WMD -2.05 mmHg, 95% CI -2.60 to -1.49, p=<0.001). Telmisartan reduced diastolic blood pressure significantly more than perindopril (WMD -2.05 mmHg) in patients with essential hypertension, with no significant difference in systolic blood pressure reduction.
Synapse has enriched 10 related papers. Consider them for comparative context: